The key to unlocking effective therapies for the unsolved diseases of our time is a deep understanding of human disease biology.
To this end, MIMETAS aims to capture the essence of diseases in fit-for-purpose in vitro models. We are fully committed to reducing human disease complexity into functional and screenable assays.
Partner with us to develop next-generation therapies. We stand shoulder to shoulder to understand disease mechanisms better.
Through risk-sharing partnerships on tailor-made phenotypic disease models, we aim to improve our understanding of disease biology and transform the drug discovery process. We do this by exploiting disease-relevant assays for screening of new targets and compounds followed by the selection of candidates, and further validation, all based on our phenotypic human models.
For more information about these partnerships, please get in touch.
Back in the Compound Era, access to phenotypically discovered compounds used to drive new drug development. In the Target Era, over the last 30 years, target discovery and compound screening took over.
Today, we can combine phenotypic models with screening capabilities in a new Disease Era, where human disease biology is central.
Our partnership with Roche
Together with Roche, we recently started a partnership to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD). We will be responsible for developing tissue-based disease models and assays in the OrganoPlate, our proprietary organ-on-chip platform that increases the predictability of biomarkers and reduces animal use in scientific testing. Roche will gain access to technology, disease models, and scientific results.